Overview of Depakote ER

Defining Depakote ER: Active Ingredient and Pharmacological Class

Property	Description
Active ingredient	Divalproex Sodium (dissociates into Valproate)
Form	Extended-Release (ER) Tablet
Pharmacological class	Anticonvulsant, Mood Stabilizing Agent
Common use	Neurological stability, Managing severe mood shifts
Origin	Synthetic, Carboxylic Acid Derivative

Depakote ER is a prescription-only medication whose active ingredient is Divalproex Sodium, a substance fundamentally classified as both an Anticonvulsant and a Mood Stabilizing Agent. This medication is a synthetic compound that chemically belongs to the carboxylic acid derivative class, placing it within the broad category of Antiepileptic Drugs (AEDs). Upon administration, the Divalproex Sodium dissociates into the active component, the valproate ion, which is the agent responsible for modulating electrical signaling in the brain. The valproate ion functions by stabilizing nerve cell activity across the central nervous system, a principle central to its therapeutic role.

The Purpose and Formulation of Divalproex Sodium

The primary purpose of Divalproex Sodium is to provide crucial neurological stability by influencing key chemical and electrical pathways. This single-ingredient product achieves stability primarily by enhancing the activity of Gamma-Aminobutyric Acid (GABA), the brain’s chief inhibitory neurotransmitter, alongside regulating the activity of voltage-gated sodium channels to prevent excessive nerve cell firing. Depakote ER is differentiated by its Extended-Release (ER) Tablet format, specifically positioned for patients requiring consistent, long-term therapeutic levels with reduced dosing frequency. The medication serves as a broad-spectrum stabilizer used in complex neurological care and is used for maintaining control over severe, abnormal brain activity, such as supporting stability for individuals experiencing cyclical, acute mood episodes. The medication is delivered as an Oral Formulation designed to ensure a slow, controlled, and sustained release of the active valproate ion over a prolonged 24-hour period.

Regulatory References

NIH/NLM Drug Information

What side effects are possible with Depakote ER?

Possible Side Effects and Safety Information

Depakote ER (divalproex sodium) carries three boxed warnings from the U.S. Food and Drug Administration (FDA) regarding potentially life-threatening risks: Hepatotoxicity (liver damage), Pancreatitis (inflammation of the pancreas), and Fetal Risk (congenital malformations and developmental deficits).

Serious Risks

Hepatotoxicity: Fatal liver failure has occurred, usually within the first six months. Children under two years old and patients with mitochondrial disorders are at a significantly higher risk. Symptoms can include malaise, weakness, facial swelling, vomiting, and loss of appetite.
Pancreatitis: Life-threatening cases of pancreatitis have been reported, sometimes resulting in death. Symptoms include severe abdominal pain, nausea, and vomiting. This can occur at any time during treatment.
Fetal Risk: Use during pregnancy can cause major congenital malformations, notably neural tube defects (e.g., spina bifida), as well as decreased IQ and other neurodevelopmental disorders. It should not be used in women of childbearing potential unless other treatments are ineffective or unacceptable, and effective contraception is used.
Suicidal Thoughts and Behaviors: Like other antiepileptic drugs, Depakote ER may increase the risk of suicidal thoughts or actions in a small percentage of patients. Close monitoring for mood or behavioral changes is essential.

Common Side Effects

The most common side effects reported (occurring in 5% of patients) include:

Body System	Side Effect Examples
Gastrointestinal	Nausea, vomiting, diarrhea, abdominal pain, dyspepsia
Neurological	Somnolence (drowsiness), dizziness, tremor, asthenia (weakness), headache
Other	Hair loss (alopecia), weight gain, infection, flu syndrome, changes in appetite

Patients should promptly contact their healthcare provider if they experience any signs of serious side effects, such as jaundice, unexplained bruising, severe abdominal pain, or significant changes in mood or behavior.

Overdose and Emergency Response

An overdose of Depakote ER (Divalproex Sodium) is considered a medical emergency that requires immediate professional attention.

The official regulatory prescribing information documents that overexposure may present with acute signs of Central Nervous System (CNS) depression, including somnolence and the potential progression to a state of deep coma. Other documented clinical manifestations include heart block and hypernatremia (elevated sodium concentration in the blood). The critical nature of overexposure is emphasized by the reported risk of fatalities linked to valproate overdose, underscoring the necessity of urgent care.

Official Emergency Response and Management

When overdose is suspected, general supportive measures must be promptly initiated with particular attention to the maintenance of vital organ function. The regulatory documents describe the potential need for specialized interventions, such as hemodialysis or tandem hemodialysis plus hemoperfusion, to significantly remove the drug, especially given the high unbound fraction of the drug in overdose situations. Procedures like gastric lavage or emesis may also be considered, with the benefit depending on the elapsed time since ingestion. The official labeling notes that no specific antidote is currently documented for valproate overdose.

Therapeutic Uses of Depakote ER

What Depakote ER Treats: Main Uses and Benefits

The therapeutic scope of Depakote ER (Divalproex Sodium Extended-Release) addresses conditions characterized by periods of heightened symptoms related to neurological or mood dysregulation. The medication is used across three primary therapeutic domains: supporting functional stability in epilepsy, addressing acute manic and mixed episodes of Bipolar Disorder, and providing preventive care for recurrent migraine headaches.

This medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as the hyperactivity of mania or the unpredictable nature of seizures. It is considered relevant for supporting functional stability and may assist with maintaining a sense of stability when symptoms are more noticeable. It contributes to easing the overall symptom load when symptoms interfere with routine activities.

It is commonly used across conditions presenting with acute episodes and helps manage symptom intensity.

Quick Fact: Relief for Episodic Neurological Strain

Quick Fact: Relief for Episodic Neurological Strain is associated with easing symptoms of increased neurological activity associated with seizures and supporting patients during difficult episodes by easing the distress of severe mood shifts.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Who can and cannot use Depakote ER? — Official Regulatory Information

Depakote ER (divalproex sodium extended-release) is contraindicated and must not be used by patients with hepatic disease or significant hepatic dysfunction or those with known urea cycle disorders. The medicine is also prohibited for patients with known mitochondrial disorders caused by POLG gene mutations, and in children under two years of age suspected of having such a disorder. Patients with a known hypersensitivity to the drug are likewise ineligible.

Use for migraine prophylaxis is strictly contraindicated in pregnant women and in women of childbearing potential who are not using effective contraception. For the treatment of epilepsy or bipolar disorder, women of childbearing potential should not be treated with Depakote ER unless other medications have failed.

Age-related restrictions exist: use in children under two years of age carries a substantially increased risk of fatal liver toxicity and should be approached with extreme caution. The drug is generally indicated for some seizure types in adults and children down to age 10.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Divalproex Sodium Extended-Release (Depakote ER) based on regulatory information.

Official Interaction Restrictions and Classifications

Category	Constraint / Classification
Prohibited/High-Risk Combination	Co-administration with Carbapenem Antibiotics (e.g., Meropenem) is associated with a rapid, significant reduction in Valproate plasma levels, which risks a loss of therapeutic effect.
Non-Medicinal Restriction	Alcohol intake is officially not recommended during Valproate treatment.
Additive Toxicity Risk	Concomitant use with Topiramate increases the official risk of Hyperammonemia and Encephalopathy.

Pharmacokinetic and Exposure-Altering Interactions

Official regulatory documents detail two main types of pharmacokinetic interactions:

Increased Drug Exposure: Valproate inhibits the metabolism of several medicines, leading to increased plasma concentrations of co-administered agents like Lamotrigine (increasing toxicity risk), Phenobarbital, and the free fraction of Phenytoin. Aspirin (salicylates) also officially increases free Valproate plasma levels via protein binding displacement.
Decreased Valproate Exposure: Other anticonvulsants, such as Phenytoin and Carbamazepine, are hepatic enzyme inducers that increase Valproate clearance, potentially reducing its therapeutic concentration. Enzyme inhibitors like Felbamate have the opposite effect, increasing Valproate exposure.

Population-Specific Notes

The official profile notes that in elderly patients and individuals with Chronic Hepatic or Renal Disease, the reduced protein binding of Valproate is documented, altering drug disposition.

Mechanism of Action

The mechanism of action for the valproate ion involves complex, multi-modal interactions primarily focused on reducing neuronal excitability and promoting long-term cellular stability across the Central Nervous System (CNS). The primary mechanism involves modulating the GABAergic system, the brain's main inhibitory network. The valproate ion acts on key enzymes, inhibiting GABA Transaminase (GABA-T) to slow GABA catabolism while stimulating Glutamic Acid Decarboxylase (GAD) to promote its synthesis. This dual action increases the functional concentration of synaptic GABA, enhancing the inhibitory tone on neurons and contributing to a reduction in overall neuronal firing frequency. A secondary mechanism focuses on directly regulating the neuron's potential for rapid discharge. The drug achieves this by blocking Voltage-Gated Sodium Channels and T-Type Calcium Channels on the nerve cell membrane. This inhibition physically limits the rapid ionic exchange necessary for sustained, high-frequency electrical impulses. This action contributes to neuronal membrane stabilization and limits the spread of high-frequency electrical activity. For sustained action, the drug engages an epigenetic pathway by inhibiting Histone Deacetylase (HDAC) enzymes. This interaction leads to increased histone acetylation, which alters gene expression related to cellular structure and plasticity. This process supports sustained changes in cellular function within the nervous system.

Dosage and Administration Information

How to Use Depakote ER: Administration Guidelines

Depakote ER (Divalproex Sodium Extended-Release) is a prescription medicine that is typically administered following specific parameters to ensure the proper delivery of the active ingredient. This section details the administration route, dosing structures, and preparation requirements.

Administration Scope

Instruction	Detail
Route of administration	Oral
Dosing schedule	Varies by indication (e.g., initial 25 mg/kg/day for mania, initial 500 mg/day for migraine prophylaxis).
Frequency	Once daily
Preparation	The tablet is swallowed whole; it is not to be crushed or chewed due to the extended-release design.

Procedural and Population-Specific Rules

The use of Depakote ER involves specific procedural parameters and adjustments for certain patient groups. The medication is available in 250 mg and 500 mg Extended-Release Tablets.

Administration Parameters:

The tablet is taken once daily, in the strength and dosage determined by a health professional.
The tablet is swallowed whole to maintain the extended-release mechanism.
Dose adjustments (titration) occur at specific intervals and rates, such as weekly increases for epilepsy treatment, until the recommended dose is reached.
Lower starting doses and slower titration are utilized for geriatric patients.
Lower total doses are applied for individuals with hepatic impairment.

These parameters establish a standardized protocol for use, focusing on the correct form of ingestion, frequency, and defined dose adjustment pathways.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Depakote ER

Evidence for Use in Acute Manic and Mixed Episodes

This section will summarize the types of controlled clinical trials, such as short-term Randomized Controlled Trials (RCTs), that have investigated the use of Depakote ER for conditions characterized by heightened symptom activity, detailing what clinical outcomes were measured.

Research exploring Depakote ER for conditions characterized by fluctuating or episodic manifestations of Bipolar Disorder has been conducted using short-term, controlled trials. Researchers primarily examined outcomes related to outcomes describing episodic or acute changes, such as measuring changes in severe symptom intensity using established rating scales like the Young Mania Rating Scale. The research describes patterns related to how symptoms evolved during the defined time intervals. Certainty remains low for long-term outcomes regarding patterns beyond the initial phase. Limited information is available on the ER formulation in children under 10 years of age.

Evidence for Use in Seizure Management (Epilepsy)

This section will describe the research structure for Depakote ER in conditions characterized by fluctuating or episodic manifestations, including trials for Complex Partial Seizures and Absence Seizures, outlining the types of studies available and the ways in which researchers monitored seizure patterns.

For research involving seizure patterns, Depakote ER was studied for conditions involving outcomes related to systemic or functional imbalance. Researchers have employed different study designs, including controlled trials comparing the medication to placebo. These trials research examined outcomes such as measuring the frequency of seizure events and tracking the proportion of individuals who experienced the measured endpoint of complete seizure cessation. It should be clarified that research on outcomes and measured changes is not established through formal studies for the treatment of seizures in children younger than 10 years of age.

Evidence for Use in Migraine Prophylaxis

This section will review the types of placebo-controlled studies and meta-analyses that have examined Depakote ER's role in scenarios related to the prevention of recurrent migraine headaches, specifically focusing on the measures used, such as the change in monthly headache frequency.

The research into Depakote ER for migraine prophylaxis (prevention) mainly involves controlled trials where participants with outcomes related to physical discomfort were studied. These placebo-controlled studies was evaluated in adults with recurring migraine headaches and typically lasted around 12 weeks. Research examined outcomes related to outcomes describing episodic or acute changes and outcomes monitoring physiological strain or stress. The follow-up durations were limited, and the research exclusively focuses on scenarios related to prevention.

What is Still Uncertain About the Research

This section will synthesize the main limitations and gaps in the existing research base for Depakote ER, describing areas such as the lack of long-term data for the ER formulation and instances where evidence may be restricted to certain age or clinical severity groups.

The existing research presents several limitations. Certainty remains low for long-term outcomes, and there is limited information for long-term outcomes that measure outcomes related to systemic or functional imbalance over multiple years, particularly for the Extended-Release formulation. Comparative evidence is lacking regarding patient outcomes when switching from the standard delayed-release form to the extended-release form for seizure control. The data for certain groups remain insufficient, especially for children under the age of 10 across all indications. Findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Depakote ER (FAQ)

Q: Is Depakote ER the same medicine as valproic acid?

According to the official product information, Depakote ER contains the active ingredient Divalproex Sodium. This compound is chemically comprised of valproic acid and sodium valproate. When the body processes the medication, the Divalproex Sodium dissociates into the valproate ion, which is the component responsible for the therapeutic effect.

Q: Are there long-term health risks associated with taking Depakote ER for several years?

Official regulatory documents list several serious warnings, such as risks of Hepatotoxicity (liver damage) and Pancreatitis (inflammation of the pancreas), which can potentially occur at any time during treatment. It is noted that the collection of common adverse event data is often limited to the duration of short-term clinical trials.

Q: Are there specific food or drink items that should be avoided with Depakote ER?

Official information indicates that alcohol intake is not recommended while a person is undergoing treatment. Additionally, the official instructions for administration mention that the tablets should not be taken with carbonated beverages. This is because carbonation may interfere with the medication’s extended-release mechanism.

Q: Can older adults or the elderly safely use Depakote ER?

Official documentation addresses the use of this medicine in older adults. It notes that lower starting doses and a gradual dose adjustment are specific considerations for geriatric patients. This is due to documented changes in how the drug is processed in older adults.

Q: Can people with kidney problems safely use Depakote ER?

Regulatory information notes that renal impairment (kidney problems) alters the drug's disposition in the body, which can reduce its protein binding. Because of this change, dose adjustment based on drug levels in the blood (serum monitoring) may be considered by a healthcare professional.

Q: What are the signs of a serious allergic reaction to Depakote ER?

Serious skin and hypersensitivity reactions are listed in official warnings. Signs of severe reactions can include a skin rash, fever, swollen glands (lymphadenopathy), or swelling of the face or tongue.

Q: What happens if a person suddenly stops taking Depakote ER?

According to the official product information, abruptly stopping this medication can cause a significant and rapid increase in seizure frequency. Therefore, official documentation emphasizes that withdrawal must be performed gradually.

Q: Is Depakote ER a brand name, or is a generic version available?

Depakote ER is the brand name of the medicine. Regulatory and government drug information sources confirm that a generic version of the medication is also available, which is officially called Divalproex Sodium Extended-Release Tablets.

Q: Why do patients need to get blood tests while taking Depakote ER?

Official guidelines state the importance of periodic monitoring of liver function tests, particularly during the first six months of treatment, due to the risk of hepatotoxicity. Official documents also mention the monitoring of serum valproate levels to confirm the appropriate amount of medicine in the blood.

Q: Can Depakote ER be used for nerve pain or other types of pain?

The medication is officially approved only for the treatment of certain types of seizures (epilepsy), manic episodes associated with bipolar disorder, and the prevention of migraine headaches. Use for nerve pain or other pain conditions is not listed as an official indication.

Q: Does Depakote ER affect fertility in men or women?

Official documents note that the medicine is associated with risks to the female reproductive system, including reports of Polycystic Ovary Syndrome (PCOS) and menstrual disorders. General risks to male fertility have also been explored in research.

Q: Does Depakote ER affect cognitive function, memory, or concentration?

Adverse reactions reported in official documents include effects on the central nervous system. These documented effects include somnolence (drowsiness), dizziness, sedation, and amnesia (memory issues).

Q: Why is Depakote ER contraindicated for people with specific liver conditions or urea cycle disorders?

The medication is contraindicated for individuals with significant hepatic disease due to the serious risk of liver damage. It is also contraindicated for those with known urea cycle disorders (UCD) because of the risk of developing a serious condition called fatal hyperammonemic encephalopathy.

Q: What does the official documentation say about taking Depakote ER with food?

The official prescribing information states that the extended-release tablets may be taken with or without food.

Q: What is the general process for discontinuing Depakote ER, according to official sources?

Official documentation states that the medication must be withdrawn gradually. This is a crucial step because abrupt discontinuation is known to increase the risk of developing seizures.

Q: Does Depakote ER affect the results of any common medical lab tests?

Official information indicates that the medication may affect the results of certain common laboratory tests. This includes tests for urinary ketones and those related to thyroid function.

Q: Why is it important to avoid taking Depakote ER with carbonated drinks?

The medication is designed as an extended-release tablet to slowly and consistently release the active ingredient over time. The official documentation states that the tablets should not be taken with carbonated beverages because carbonation may interfere with this extended-release mechanism.

Q: How long does Depakote ER stay in a person's system after they stop taking it?

The time the active substance stays in the body is documented in official pharmacological data. The elimination half-life of the valproate ion, which is the active component, is generally described as being in the range of 9 to 16 hours.

Q: What are the common misunderstandings about the extended-release formulation of this drug?

Misunderstandings often relate to the official rules for taking the medicine. Official documentation states that the tablet must be swallowed whole and is not to be chewed, crushed, or split due to its extended-release design.

How should Depakote ER be stored and disposed of?

The official labeling for Depakote ER (divalproex sodium extended-release tablets) specifies the required storage and disposal conditions.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with excursions permitted up to 30 C (86 F). Do not refrigerate or expose to excessive heat.
Protection	Keep the container tightly closed and protect the tablets from light and moisture.
Child Safety	Keep out of the reach and sight of children and store the medication locked up.

Disposal Instructions

Unused or expired Depakote ER must be disposed of according to local, state, and federal regulations. The regulatory guidance instructs patients to utilize a drug take-back program when available. To protect the environment, disposal should prevent discharge into drains or wastewater systems.

Depakote ER